Conditions: Uveitis
Keywords: Active uveitis intermediate uveitis panuveitis posterior uveitis uveitis
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 30
Healthy volunteers: no

Brief summary:
This study will assess the safety and efficacy of AIN457 as adjunctive therapy for the treatment of intermediate uveitis, posterior uveitis, or panuveitis requiring systemic immunosuppression.

Detailed description:

Arms:
arm 1: AIN457 300 mg s.c. at baseline, Week 1 and Week 2, then every 2 weeks. arm 2: AIN457 300 mg s.c. at baseline and Week 2, then every 4 weeks. arm 3: AIN457 150 mg s.c. at baseline and Week 2, then every 4 weeks arm 4: Placebo s.c at baseline, Week 1 and Week 2, then every 2 weeks

Interventions: intervention 1: AIN457 intervention 2: AIN457 intervention 3: AIN457 intervention 4: Placebo
Intervention descriptions: intervention 1: None intervention 2: None intervention 3: None intervention 4: None

Protocol document: